Femoston conti mini film-coated tablets 2.5 mg/0.5 mg blister 28 pcs

Active ingredients: dydrogesterone; estradiol;

1 tablet contains 2.5 mg of micronized dydrogesterone and micronized estradiol hemihydrate, which is equivalent to 0.5 mg of estradiol;

Excipients: lactose monohydrate, hypromellose (HPMC 2910), corn starch, colloidal silicon dioxide, magnesium stearate, film coating Yellow 1 (macrogol 3350, polyvinyl alcohol, talc, titanium dioxide (E 171), iron oxide yellow (E172)).

• known hypersensitivity to the active substances or to any of the excipients of the drug;
• diagnosed in the past, present or suspected breast cancer;
• established or suspected estrogen-sensitive tumors (e.g. endometrial cancer);
• vaginal bleeding of unclear origin;
• untreated endometrial hyperplasia;
• active venous thromboembolism in history (deep vein thrombosis, pulmonary embolism);
• the presence of thrombophilic disorders (for example, protein C, protein S, or antithrombin deficiency);
• acute or recent thromboembolic arterial disease (e.g. angina pectoris, myocardial infarction);
• acute liver disease or a history of liver disease in which liver function tests have not returned to normal;
• porphyria.

For internal use.

Long-term use of the combination: estrogen and progestogen are taken daily without a break. You should take one tablet per day for a 28-day cycle.

Femoston conti mini should be taken continuously, without interruption in taking tablets from different packages.

To begin with, the lowest effective dose should be used for the shortest possible period of time to initiate and continue treatment of postmenopausal symptoms.

Pregnant women

The drug is not indicated for use during pregnancy.

Children

The drug is not intended for use in children.

Drivers

The drug has no or negligible influence on the ability to drive or operate complex machinery.

Both estradiol and dydrogesterone are substances with low toxicity. Symptoms of overdose may include nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue and withdrawal bleeding. It is unlikely that any specific or symptomatic treatment will be required in case of overdose. The information described above also applies to cases of overdose in children.

The most common adverse reactions in patients treated with estradiol/dydrogesterone in clinical trials were headache, abdominal pain, breast pain/tenderness, and back pain.

Drug interaction studies have not been conducted.

Keep out of reach of children.

Does not require special storage conditions.

Shelf life – 4 years.